MCC-135

DRUG2 trials

Sponsors

Takeda, Tanabe Pharma Corporation

Conditions

Congestive Heart FailureMyocardial Infarction

Phase 2

Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.

CompletedNCT00050076

TakedaCongestive Heart Failure

Start: 2002-08-31End: 2003-08-31Updated: 2012-02-02

MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients

CompletedNCT00078013

Tanabe Pharma CorporationMyocardial Infarction

Start: 2003-04-30End: 2004-08-31Target: 414Updated: 2005-06-24